By: Lucio, et al. S.B. No. 394 (Klick, Noble, Oliverson, Bonnen, Frank, et al.)

## A BILL TO BE ENTITLED

1 AN ACT

- 2 relating to abortion complication reporting and the regulation of
- 3 drug-induced abortion procedures, providers, and facilities;
- 4 creating a criminal offense.
- 5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
- 6 SECTION 1. The legislature finds that:
- 7 (1) this state has an interest to protect the health
- 8 and welfare of every woman considering a drug-induced abortion;
- 9 (2) the use of Mifeprex or mifepristone presents
- 10 significant medical complications including, but not limited to,
- 11 uterine hemorrhage, viral infections, abdominal pain, cramping,
- 12 vomiting, headache, fatigue, and pelvic inflammatory disease; and
- 13 (3) the risk of failure rate and complications
- 14 increases with advancing gestational age.
- SECTION 2. Sections 171.006(a) and (b), Health and Safety
- 16 Code, as added by Chapter 4 (H.B. 13), Acts of the 85th Legislature,
- 17 1st Called Session, 2017, are amended to read as follows:
- 18 (a) In this section, "abortion complication" or "adverse
- 19 event" means any harmful event or adverse outcome with respect to a
- 20 patient related to an abortion that is performed or induced on the
- 21 patient and that is diagnosed or treated by a health care
- 22 practitioner or at a health care facility and includes:
- 23 (1) shock;
- 24 (2) uterine perforation;

S.B. No. 394

1	(3)	cervical laceration;	
2	(4)	hemorrhage;	
3	(5)	aspiration or allergic response;	
4	(6)	infection;	
5	(7)	sepsis;	
6	(8)	death of the patient;	
7	(9)	<pre>incomplete abortion;</pre>	
8	(10)	damage to the uterus; [ <del>or</del> ]	
9	(11)	an infant born alive after the abortion;	
10	(12)	blood clots resulting in pulmonary embolism or	
11	1 <u>deep vein thrombosis;</u>		
12	<u>(13)</u>	failure to actually terminate the pregnancy;	
13	(14)	pelvic inflammatory disease;	
14	(15)	endometritis;	
15	(16)	missed ectopic pregnancy;	
16	(17)	cardiac arrest;	
17	(18)	respiratory arrest;	
18	<u>(19)</u>	renal failure;	
19	(20)	metabolic disorder;	
20	(21)	embolism;	
21	(22)	coma;	
22	(23)	placenta previa in subsequent pregnancies;	
23	(24)	preterm delivery in subsequent pregnancies;	
24	<u>(25)</u>	fluid accumulation in the abdomen;	
25	<u>(26)</u>	hemolytic reaction resulting from the	
26	26 administration of ABO-incompatible blood or blood products;		
27	(27)	adverse reactions to anesthesia or other drugs;	

- 1 <u>or</u>
- 2 (28) any other adverse event as defined by the United
- 3 States Food and Drug Administration's criteria provided by the
- 4 MedWatch Reporting System.
- 5 (b) The reporting requirements of this section apply only
- 6 to:
- 7 (1) a physician who:
- 8 (A) performs <u>or induces</u> at an abortion facility
- 9 an abortion that results in an abortion complication diagnosed or
- 10 treated by that physician; or
- 11 (B) diagnoses or treats [at an abortion facility]
- 12 an abortion complication that is the result of an abortion
- 13 performed or induced by another physician [at the facility]; or
- 14 (2) a health care facility that is a hospital,
- 15 abortion facility, freestanding emergency medical care facility,
- 16 or health care facility that provides emergency medical care, as
- 17 defined by Section 773.003.
- 18 SECTION 3. Section 171.061, Health and Safety Code, is
- 19 amended by amending Subdivisions (2) and (5) and adding
- 20 Subdivisions (2-a) and (8-a) to read as follows:
- 21 (2) "Abortion-inducing drug" means a drug, a medicine,
- 22 or any other substance, including a regimen of two or more drugs,
- 23 medicines, or substances, prescribed, dispensed, or administered
- 24 with the intent of terminating a clinically diagnosable pregnancy
- 25 of a woman and with knowledge that the termination will, with
- 26 reasonable likelihood, cause the death of the woman's unborn child.
- 27 The term includes off-label use of drugs, medicines, or other

- 1 substances known to have abortion-inducing properties that are
- 2 prescribed, dispensed, or administered with the intent of causing
- 3 an abortion, including the Mifeprex regimen, misoprostol
- 4 (Cytotec), and methotrexate. The term does not include a drug,
- 5 medicine, or other substance that may be known to cause an abortion
- 6 but is prescribed, dispensed, or administered for other medical
- 7 reasons.
- 8 <u>(2-a) "Adverse event" or "abortion complication"</u>
- 9 means any harmful event or adverse outcome with respect to a patient
- 10 related to an abortion, including the abortion complications listed
- 11 in Section 171.006, as added by Chapter 4 (H.B. 13), Acts of the
- 12 85th Legislature, 1st Called Session, 2017.
- 13 (5) "Medical abortion" means the administration or use
- 14 of an abortion-inducing drug to induce an abortion, and may also be
- 15 referred to as a "medication abortion," a "chemical abortion," a
- 16 "drug-induced abortion," "RU-486," or the "Mifeprex regimen".
- 17 (8-a) "Provide" means, when used regarding
- 18 abortion-inducing drugs, any act of giving, selling, dispensing,
- 19 administering, transferring possession, or otherwise providing or
- 20 prescribing an abortion-inducing drug.
- 21 SECTION 4. Section 171.063, Health and Safety Code, is
- 22 amended by amending Subsections (a), (c), and (e) and adding
- 23 Subsection (b-1) to read as follows:
- 24 (a) A person may not knowingly [qive, sell, dispense,
- 25 administer, provide[, or prescribe] an abortion-inducing drug to a
- 26 pregnant woman for the purpose of inducing an abortion in the
- 27 pregnant woman or enabling another person to induce an abortion in

- 1 the pregnant woman unless:
- 2 (1) the person who [gives, sells, dispenses,
- 3 administers, provides[, or prescribes] the abortion-inducing drug
- 4 is a physician; and
- 5 (2) [except as otherwise provided by Subsection (b),
- 6 the provision[, prescription, or administration] of the
- 7 abortion-inducing drug satisfies the protocol [tested and]
- 8 authorized by this subchapter [the United States Food and Drug
- 9 Administration as outlined in the final printed label of the
- 10 abortion-inducing drug].
- 11 (b-1) A manufacturer, supplier, physician, or any other
- 12 person may not provide to a patient any abortion-inducing drug by
- 13 courier, delivery, or mail service.
- 14 (c) Before the physician [gives, sells, dispenses,
- 15 administers, provides (, or prescribes) an abortion-inducing drug,
- 16 the physician must:
- 17 <u>(1)</u> examine the pregnant woman <u>in person;</u>
- 18 (2) independently verify that a pregnancy exists;
- 19 (3) [and] document, in the woman's medical record, the
- 20 gestational age and intrauterine location of the pregnancy to
- 21 determine if an ectopic pregnancy exists;
- 22 (4) determine the pregnant woman's blood type, and for
- 23 a woman who is Rh negative, offer to administer Rh immunoglobulin
- 24 (RhoGAM) at the time the abortion is performed or induced to prevent
- 25 Rh incompatibility, complications, or miscarriage in future
- 26 pregnancies;
- 27 (5) document whether the pregnant woman received

- 1 treatment for Rh negativity, as diagnosed by the most accurate
- 2 standard of medical care; and
- 3 (6) ensure the physician does not provide an
- 4 abortion-inducing drug for a pregnant woman whose pregnancy is more
- 5 than 49 days of gestational age.
- 6 (e) A [The] physician who [gives, sells, dispenses,
- 7 administers, provides[, or prescribes] the abortion-inducing
- 8 drug, or the physician's agent, must schedule a follow-up visit for
- 9 the woman to occur not later [more] than the 14th day [14 days]
- 10 after the earliest date on which the abortion is performed or
- 11 <u>induced or the drug is administered</u> [administration] or used [use
- 12 of the drug]. At the follow-up visit, the physician must:
- 13 (1) confirm that the woman's pregnancy is completely
- 14 terminated; and
- 15 (2) assess any continued blood loss [the degree of
- 16 bleeding].
- 17 SECTION 5. Subchapter D, Chapter 171, Health and Safety
- 18 Code, is amended by adding Sections 171.0631, 171.0632, 171.065,
- 19 and 171.066 to read as follows:
- Sec. 171.0631. VOLUNTARY AND INFORMED CONSENT REQUIRED. A
- 21 person may not provide an abortion-inducing drug to a pregnant
- 22 woman without satisfying the applicable informed consent
- 23 requirements of Subchapter B.
- Sec. 171.0632. REPORTING REQUIREMENTS. A physician who
- 25 provides an abortion-inducing drug must comply with the applicable
- 26 physician reporting requirements under Section 245.011.
- 27 Sec. 171.065. CRIMINAL OFFENSE. (a) A person who

- 1 intentionally, knowingly, or recklessly violates this subchapter
- 2 commits an offense. An offense under this subsection is a state
- 3 jail felony.
- 4 (b) A pregnant woman on whom a drug-induced abortion is
- 5 attempted, induced, or performed in violation of this subchapter is
- 6 not criminally liable for the violation.
- 7 (c) Conduct constituting an offense under this section may
- 8 also be the basis for an administrative violation under Section
- 9 171.064.
- Sec. 171.066. ENFORCEMENT OF SUBCHAPTER. A state executive
- 11 or administrative official may not decline to enforce this
- 12 subchapter, or adopt a construction of this subchapter in a way that
- 13 narrows its applicability, based on the official's own beliefs on
- 14 the requirements of the state or federal constitution, unless the
- 15 official is enjoined by a state or federal court from enforcing this
- 16 <u>subchapter</u>.
- 17 SECTION 6. The following provisions of the Health and
- 18 Safety Code are repealed:
- 19 (1) Sections 171.061(3) and (6); and
- 20 (2) Section 171.063(b).
- 21 SECTION 7. (a) Nothing in this Act shall be construed as
- 22 creating or recognizing a right to abortion.
- 23 (b) It is not the intention of this Act to make lawful an
- 24 abortion that is otherwise unlawful.
- 25 (c) Nothing in this Act repeals, replaces, or otherwise
- 26 invalidates existing Texas laws, regulations, or policies.
- 27 SECTION 8. Any provision of this Act held to be invalid or

- 1 unenforceable by its terms or as applied to any person or
- 2 circumstance shall be construed so as to give the provision the
- 3 maximum effect permitted by law, unless such holding is one of utter
- 4 invalidity or unenforceability, in which event the provision shall
- 5 be considered severable from the other provisions of this Act and
- 6 shall not affect the remainder or the application of the provisions
- 7 to other persons not similarly situated or to other, dissimilar
- 8 circumstances.
- 9 SECTION 9. (a) Except as provided by Subsection (b) of this
- 10 section, the changes in law made by this Act apply only to an
- 11 abortion performed or induced on or after the effective date of this
- 12 Act.
- 13 (b) Section 171.065, Health and Safety Code, as added by
- 14 this Act, applies only to an abortion performed or induced on or
- 15 after September 1, 2021.
- 16 SECTION 10. This Act takes effect immediately if it
- 17 receives a vote of two-thirds of all the members elected to each
- 18 house, as provided by Section 39, Article III, Texas Constitution.
- 19 If this Act does not receive the vote necessary for immediate
- 20 effect, this Act takes effect September 1, 2021.